FDA
EMA
MHRA
PMDA
Health Canada

Clinical

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Competitive

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Markets

Pricing
Access
Commercial
Launch Tracking

M&A Watch

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

Intelligence powered by the Humanexa engine.

Asset / Drug

Sugammadex

Drug and asset intelligence for Sugammadex with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 3
Catalysts: 1
Stage: Development stage unavailable

Sponsor company

Lupin →

Recent signals(3)

CompetitiveAugust 1, 2026

FDA Grants Approval for Sugammadex Sodium ANDA214319 by Sun Pharma

The FDA has granted approval for Sugammadex Sodium under application ANDA214319 submitted by Sun Pharma.

RegulatoryAugust 1, 2026

Lupin's Sugammadex Sodium ANDA214338 Receives Approval Status

Lupin's ANDA214338 for Sugammadex Sodium has received an approval status of AP from the FDA.

RegulatoryJuly 14, 2026

FDA Submission Update for Sugammadex by Tamarang SA

Tamarang SA has submitted an original ANDA for Sugammadex, currently under standard review.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(1)

Topline Data

— Sugammadex

July 14, 2026 · N/A

Indications

No related entities indexed yet.

Therapeutic areas

Anesthesia →

Anesthesia · Neuromuscular Blockade →

Neuromuscular Blockade →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.